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outcomes, RCT estimates may overestimate the effective-
ness of treatments in practice. Instrumental Variable (IV) es-
timation techniques applied to retrospective healthcare data
can yield unbiased treatment estimates for patients at the
“extensive margin” of practice. As a result, it can be shown
that IV estimates are better suited to evaluate the cost-effec-
tiveness of policies that modify existing treatment rates.
OBJECTIVE: To estimate cost-effectiveness ratios using
treatment estimates from IV techniques and contrast these
results to cost-effectiveness ratios obtained using RCT esti-
mates.
METHODS: Data from 18,795 Iowa Medicaid eligible
children with an index event of acute otitis media (AOM)
from 1989 to 1995 were collected. Instrumental variables
were constructed for each patient based on their relative
access to various provider types. IV estimates were used
to estimate cost-effectiveness ratios for AOM patients on
the extensive margin.
RESULTS: For these patients, IV estimates of the differ-
ence in cure rates between patients that were treated with
antibiotics and those not treated ranged from 11% to
13% and were statistically significant from zero at the 1%
level. These estimates are less than 15% difference in cure
rates from RCTs (Rosenfeld et al. Journal of Pediatrics.
1994). Using the average antibiotic prescription charge ob-
served from our sample, IV estimates translate into cost-
effectiveness ratios between $123 and $145 per additional
cured patient. In contrast, the RCT estimate yields a cost-
effectiveness ratio of $107 per additional cured patient.
CONCLUSION: If patients are heterogenous with re-
spect to treatment outcomes, cost-effectiveness ratios es-
timated using RCT treatment estimates will understate
the costs per outcome from changing existing treatment
rates. IV estimation with retrospective data provides a
useful alternative for policy-makers to evaluate costs per
outcome at the margins of practice.
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OBJECTIVE: Cost-effectiveness of strategies for treating
hepatitis C.
METHODS: A decision analytic Markov model was cre-
ated comparing strategies employing interferon and inter-
feron  ribavirin: 1) IFN  interferon, 12 months; 2)
IFN/CMB  interferon 12 months, followed by 6 months
of combination therapy (interferon  ribavirin) for IFN
failures; 3) IFN/CMB-R  interferon 12 months, fol-
lowed by 6 months of combination therapy for IFN re-
lapsers; 4) CMB  combination therapy, 6 months; 5)
CMB-G  genotyping, followed by 12 months of combi-
nation therapy for genotype 1, 6 months for others. In-
terferon therapy was stopped after 3 months for non-
responders. Sustained virologic response (SVR) 6 months
post-treatment was considered to be a cure. There were
seven Markov states: well, chronic hepatitis C, compen-
sated cirrhosis, decompensated cirrhosis, hepatic cellular
carcinoma, liver transplantation, dead. Only direct medi-
cal costs were considered. Model parameters were from
published literature, utility assessments of patients, Medi-
care fee schedules, and wholesale drug prices. Patients
were followed until death. Costs and health benefits were
discounted at 3%. Sensitivity analyses were performed
using 95% CIs for probabilities, doubling and halving
cost parameters, and wide ranges for utilities.
RESULTS: The genotyping (CMB-G) strategy produced
the highest SVR. Despite having the highest cost, its in-
cremental cost-effectiveness ratio (ICER) was just $7552/
QALY (quality-adjusted life-year) compared to the sec-
ond best strategy, IFN/CMB. All other strategies were
dominated. The model was only sensitive to the response
of genotype 1 to combination therapy. As the initial re-
sponse rate of genotype 1 approaches the lower limit of
the 95% CI, interferon followed by combination therapy
(IFN/CMB) became cost-effective, with the ICER of geno-
typing reaching $137,000/QALY.
CONCLUSION: Combination therapy, with duration
based on genotype, is the most cost-effective treatment of
chronic hepatitis C.
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OBJECTIVE: To compare additional antibiotic usage for
subjects randomized to Clari or Azi for the treatment of
S. pyogenes pharyngitis/tonsillitis.
METHOD: Subjects with symptoms of streptococcal
pharyngitis/tonsillitis and S. pyogenes positive were en-
rolled in a randomized, multicenter, investigator blind,
parallel comparative control study of 10 days Clari
(250mg bid) versus 5 days Azi (250mg bid on day 1 then
qd on days 2–5). Subjects were evaluated at the end of
the treatment, at 2 weeks and at 5 weeks. Clinical and
bacteriological evaluations as well as additional or con-
comitant antibiotics were evaluated at each visit.
RESULTS: A total of 525 subjects aged 12 years and older
were enrolled and randomized (Clari n  260; Azi n 
265). The bacteriological eradication and clinical cure
rates for Clari and Azi were 94% [195 of 207] versus 77%
[155 of 202] (p  0.001) and 98% [200 of 205] versus
90% [182 of 202] (p  0.002), respectively, based on per-
protocol analysis. A total of 445 subjects (Clari n  221;
Azi n  224) were evaluable for the intent-to-treat analy-
sis. There was a greater rate of additional antibiotic usage
